Addressing proteolytic efficiency in enzymatic degradation therapy for celiac disease - BSI

470 Weber St. N., Suite 204, Waterloo, ON, Canada N2L 6J2

Call Us: 1-855-885-8288

Home
About Us
- About Us
- News
- Conferences
- Careers
Products
Free Trial
- Download PEAKS Studio
Help & Support
Contact Us

Addressing proteolytic efficiency in enzymatic degradation therapy for celiac disease

On August 2, 2016February 7, 2017By BSIIn User Publications

Rey, M., et al. Addressing proteolytic efficiency in enzymatic degradation therapy for celiac disease. Scientific Reports. 30980. 02/08/2016.

Characterization of a heat-resistant extracellular protease from Pseudomonas fluorescens 07A shows that low temperature treatments are more effective in deactivating its proteolytic activityCharacterization of a heat-resistant extracellular protease from Pseudomonas fluorescens 07A shows that low temperature treatments are more effective in deactivating its proteolytic activityAmblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXaand induces anticoagulation in vitro and in vivo

Share this post?

Tweet

About author

BSI (BSI)

Leave a Reply Cancel Reply

Your email address will not be published.

Name *

Email *

Website

Tweets by @PEAKSProteomics

Socials

Facebook
LinkedIn
Twitter
Blogger
YouTube

Solutions

Products & Services
PEAKS Studio
PEAKS Online
PEAKS CMD
PEAKS AB Software

Help

Online Training
Workshops
FAQ
User Manuals
Contact Us

Contact

Bioinformatics Solutions Inc.
470 Weber St. N., Suite 204 Waterloo, ON, Canada N2L 6J2
Phone: 1-855-885-8288
Office Hours: 9:00am - 5:00pm
Privacy Policy

© 2018. Bioinformatics Solutions Inc.